Miami Beach, Fla., June 8, 2012: Piramal Imaging SA, a subsidiary of Piramal Healthcare Limited [NSE: PIRHEALTH, BSE: 500302], will present data on several compounds from its molecular imaging portfolio at the Society of Nuclear Medicine's 59th annual meeting in Miami Beach, Fla., from June 9 - 13. Data from five florbetaben studies will be featured, including results from a pivotal Phase III trial which will provide the basis for regulatory submission later this year.
Earlier this spring, Piramal Imaging was formed through the acquisition of worldwide rights to the molecular imaging research and development portfolio of Bayer Pharma AG. Florbetaben, a late-stage amyloid imaging agent being studied as a potential tool to aid in the diagnosis and assessment of Alzheimer's disease, is the lead compound in the portfolio.
Historically, the only way to definitively diagnose Alzheimer's disease has been after death – at autopsy – through analysis and identification of beta-amyloid in brain tissue. The global Phase III trial employed a unique and rigorous study design comparing in vivo brain positron emission tomography (PET) imaging with florbetaben to post-mortem analysis of the brain tissue. Another study compared florbetaben scans of people with mild cognitive impairment (MCI) over time to assess their risk of developing Alzheimer's disease.
"What better way to introduce Piramal Imaging to the nuclear medicine community," says Dr. Ludger M. Dinkelborg, CEO Piramal Imaging. "We believe we have the richest molecular imaging portfolio in the industry today, and the range of research we are presenting here reflects the depth, diversity and clinical relevance of our pipeline." Before co-founding Piramal Imaging, Dr. Dinkelborg served as Head of Diagnostic Imaging Research and Head of Molecular Imaging at Bayer Healthcare.
Piramal Imaging is developing an innovative and proprietary tracer portfolio to address major clinical needs in Alzheimer's disease, prostate cancer, lung cancer, liver cancer, and cardiovascular disease.
"Our goal is to be a leader in molecular imaging through increased diagnostic accuracy of serious medical conditions to improve patient care," says Dr. Swati A. Piramal, Director, Piramal Healthcare Limited. "On a parallel track with our aggressive clinical development program, we are taking the necessary steps toward bringing our tracers to market through the formation of strategic partnerships." Dr. Piramal was recently elected to the Harvard Board of Overseers and also serves on the Dean's Advisory Board of both the Harvard School of Public Health and Harvard Business School.
At this meeting, research on several of the company's pipeline compounds will be featured, including:
NOTE TO EDITORS: All data is embargoed until the date/time of presentation.
Multicentre phase 3 trial on florbetaben for β-amyloid brain PET in Alzheimer disease [Abstract #41] Oral Presentation: Neuroscience Miscellaneous & New Approaches Sunday, June 10, 1:57 PM - 2:09 PM, Room B217/218 Presenter: Osama Sabri, University of Leipzig, Leipzig, Germany
Longitudinal assessment of cerebral amyloid-β deposition in APP-Swe mice with [18F]florbetaben PET [Abstract #92] Oral Presentation: Brain Imaging Council Young Investigator Award Symposium Sunday, June 10, 5:03 PM - 5:15 PM, Room B217/218 Presenter: Axel Rominger, University of Munich, Munich, Germany
Partial volume effect correction of florbetaben β-amyloid (Aβ) PET data improves discrimination between Alzheimer's disease (AD) patients and healthy volunteers (HVs) [Abstract #146] Oral Presentation: Quantifying Brain Amyloid Signal - Methods & Challenges Monday, June 11, 10:24 AM - 10:36 AM, Room B217/218 Presenter: Henryk Barthel, University of Leipzig, Leipzig, Germany
A two-year longitudinal assessment of Aβ deposition in MCI with 18F-Florbetaben [Abstract #148] Oral Presentation: Quantifying Brain Amyloid Signal - Methods & Challenges Monday, June 11, 10:48 AM - 11:00 AM, Room B217/218 Presenter: Kevin Ong, Centre for PET, Austin Health, Melbourne, VIC, Australia
In vivo PET imaging of β-amyloid plaques in an APP/PS1 mouse model of Alzheimer's disease: Comparison of [18F]FIBT and [18F]Florbetaben with [11C]PiB [Abstract #1630] Poster Presentation: Probes for Neuroimaging Sunday, June 10, 7:04 PM - 7:06 PM, Exhibit Hall A-B Presenter: Behrooz Hooshyar Yousefi, Technische Universität München, Munich, Germany
Correlation of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate ([18F]FSPG) uptake by positron emission tomography (PET) with immunohistochemical expression of system xC- and CD44 in cancer patients [Abstract #219] Oral Presentation: Basic Science (Oncology); Tumor Characterization & Microenvironment Monday, June 11, 5:18 PM - 5:30 PM, Room B118/119 Presenter: Dae Hyuk Moon, University of Ulsan College of Medicine, Seoul, Republic of Korea
Evaluation of the 18F L-glutamate derivative 18F-FSPG (BAY 94-9392) in lymphoma and colon cancer patients [Abstract #1126] Poster Presentation: Meet the Author Poster Session; Basic Science (Oncology) Monday, June 11, 2:30 PM - 4:00 PM, Exhibit Hall A-B Presenter: Meena Kumar, Stanford University Medical Center, Palo Alto, California, USA
Evaluation of the 18F-labeled L-glutamate derivative 18F-FSPG (BAY 94-9392) in brain and head and neck cancer patients [Abstract #274] Oral Presentation: Basic Science (Oncology); Novel Imaging Agents - Clinical Tuesday, June 12, 8:36 AM - 8:48 AM, Room B118/119 Presenter: Meena Kumar, Stanford University Medical Center, Palo Alto, California, USA
Characterization of physiological 18F-FSPG uptake in healthy volunteers: Kinetics and biodistribution [Abstract #555] Oral Presentation: Technological Advances, Methodology, Quantification Wednesday, June 13, 10:33 AM - 10:45 AM, Room B118/119 Presenter: Camila Mosci, Stanford University, Palo Alto, California, USA
Ga68-Bombesin Preclinical validation of the Ga-68-Bombesin Antagonist BAY 86-7548 for a Phase I Study in Prostate Cancer Patients [Abstract #177] Oral Presentation: Prostate Monday, June 11, 12:30 PM - 12:42 PM, Room B214 Presenter: Sandra Borkowski, Global Drug Discovery, Bayer Healthcare, Berlin, Germany
Radiosynthesis and pre-clinical evaluation of Al18F labeled bombesin antagonist: Promising tracer for prostate cancer imaging [Abstract #1732] Poster Presentation: Special Meet the Author Poster Session; Probes for Oncology Sunday, June 10, 6:30 PM - 8:00 PM, Exhibit Hall A-B Presenter: Svetlana Selivanova, Center for Radiopharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
Clinical investigation of dynamic PET/CT imaging using O-([18F]fluoromethyl)-D-tyrosine (D-18F-FMT, BAY 86-9596) in oncological patients [Abstract #1676] Poster Presentation: Special Meet the Author Poster Session; Probes for Oncology Sunday, June 10, 6:30 PM - 8:00 PM, Exhibit Hall A-B Presenter: Irene Burger, University Hospital, Zurich, Switzerland
Comparison of PET/CT images with a novel tracer O-([18F]fluoromethyl)-D-tyrosine (D-18F-FMT, BAY 86-9596) with LAT1 immunohistochemical staining in patients with non-small cell lung cancer or head and neck squamous cell carcinoma [Abstract #1677] Poster Presentation: Special Meet the Author Poster Session; Probes for Oncology Sunday, June 10, 6:30 PM - 8:00 PM, Exhibit Hall A-B Presenter: Irene Burger, University Hospital, Zurich, Switzerland